BioCentury | Jan 21, 2021
Politics, Policy & Law

Promising to put science first, Woodcock takes over as acting FDA commissioner

Within a few hours of his inauguration, President Joe Biden put a slate of public health officials in place. Most are serving on an acting basis pending nomination and Senate confirmation of permanent...
BioCentury | Jan 20, 2021
Politics, Policy & Law

Exit interview: Hahn departs after tumultuous tenure, advocating greater independence for FDA

FDA Commissioner Stephen Hahn presided over the most tumultuous era in FDA’s history, one that will be remembered for the agency’s failure to take aggressive actions at the start of the COVID-19 outbreak,...
BioCentury | Jan 16, 2021
Management Tracks

FDA’s Schiller joins Aetion; plus Novavax, NHC, NextCure, Ziopharm, ONK

Lowell Schiller left FDA to join Aetion Inc. as chief legal and regulatory officer.  For nearly the past two years, Schiller was principal associate commissioner for policy, serving briefly as acting chief counsel at the agency....
BioCentury | Jan 16, 2021
Politics, Policy & Law

Woodcock’s appointment as acting FDA commissioner could be audition for permanent position

Politics, Policy & Law When Janet Woodcock moves into the FDA commissioner’s office next week, she will take charge, at least on an acting basis, of an agency that has been pummeled for months. President...
BioCentury | Jan 16, 2021
Finance

Greenwood-led fund to allow Dana-Farber to invest later in homegrown IP

Luba Greenwood, the Roche and Verily alum turned fund manager, told BioCentury that Dana-Farber’s new $10 million fund will give the institute a vehicle that allows it to participate in later rounds for its spinouts. The new...
BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

While it’s too early to say whether 2020’s record year of fund-raising constitutes a “new normal,” there’s consensus among buysiders and bankers that a cheap money environment will continue in 2021 as...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

A broad syndicate has funded NewAmsterdam with a $196 million (€160 million) series A round to assess whether a well-traveled CETP inhibitor can find a place in the treatment paradigm for dyslipidemia. Forbion, Morningside Ventures...
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer vaccines in combination with...
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

EQRx is planning to deliver on its promise to provide equivalent or better low-cost drugs ahead of schedule with a $500 million series B, with diverse investor interest reflecting a mission that has only...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...
Items per page:
1 - 10 of 3088